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Several prognostic factors are used in chronic lymphocytic
leukemia (CLL) to predict disease progression at diagnosis and
to help guide therapeutic choices. Among these factors, the
detection of deletions of the short arm of chromosome 17, where
the tumor suppressor gene TP53 is located at the 17p13 locus,
predicts resistance to standard treatments and poor prognosis.
1
Deletions of 17p13 are observed in 5–7% of CLL patients at
diagnosis and in 25–40% of cases with advanced refractory
disease. Other markers of poor prognosis have been described,
such as unmutated IGHV gene status, high levels of thymidine
kinase and soluble CD23, CD38 and ZAP-70 expression, as well
as other chromosomal aberrations, such as 11q23 deletion.
However, defects in the TP53 pathway consistently appear as the
most signiﬁcant adverse prognostic factor in CLL.
2
About 80% of patients with 17p13 deletion display a mutation
in the remaining TP53 allele, resulting in loss of function of the
p53 protein, but mutations without a deletion are observed in
4–5% of cases.
3 Mutations of TP53 have been identiﬁed that are
consequently associated with an unfavorable outcome, but all
mutations do not predict similar consequences on the p53
pathway. In addition, a minority of patients with 17p13 deletion
have an indolent clinical course, suggesting that p53 function is
preserved. Finally, it has appeared that p53 dysfunction is the
result of several intricate factors that have not been clearly
deﬁned, and several questions still remain to be addressed
regarding the biological consequences of TP53 deletions and the
various types of mutations.
Consequently, it has become evident that new techniques to
determine p53 function are required to identify patients with
TP53 abnormalities (deletion and/or mutation), despite normal
function, and patients who have TP53 neither mutated nor
deleted, but which is dysfunctional for other reasons, including
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Figure 1 Cytometric functional test for p53/p21 proteins in cells from patients with chronic lymphocytic leukemia (CLL). Proﬁles of response after
24-h in vitro culture of CLL cells in the presence of etoposide and nutlin-3a. (a) Type 1 proﬁle: normal p53 function with undetectable p53 protein
on day 0, p53 and p21 increased by day 1. (b) B cells from a representative type 1 proﬁle were untreated (red) or treated with etoposide and
nutlin-3a for 6 h (blue), and p53 Serine 15 phosphorylation was assessed by ﬂow cytometry. (c) Type 2 abnormal proﬁle, with a high baseline level
of p53 protein and no increase in p53/p21 by day 1. (d) Type 3 abnormal proﬁle, with undetectable baseline p53 protein and no increase in
p53/p21 by day 1.
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These considerations prompted us to determine in a series of 37
CLL patients the functional status of p53 by using a cytometric
method that was adapted from the methodology previously
described by Best et al.
4 We then compared results with the
cytogenetic data and mutational status of TP53 of this
population of patients.
Determination of the functional status of p53 in CLL cells by
ﬂow cytometry was based on induction of p53 and p21 protein
expression using etoposide and nutlin-3a. Three types of
response were observed. The type 1 proﬁle corresponded to
normal function (Figure 1a): as expected the baseline expression
of p53 on day 0 was undetectable (threshold: mean ﬂuorescence
intensity o100), but by day 1, a clear-cut increase in the
percentage of p53 expression was observed (increased from 100
to 600%). In parallel, a moderate increase of p21 expression was
also observed on day 1 (410%). To conﬁrm the functionality of
p53 protein, we tested its phosphorylation at Serine 15 in
response to etoposide and nutlin-3a treatment (Figure 1b). This
phosphorylation, which results in p53 stabilization and accu-
mulation in the nucleus, is a typical hallmark showing p53
activation.
5 The type 2 proﬁle (Figure 1c) was deﬁned by a high
level of p53 protein on day 0 without any (or with a slight)
increase in p53 or p21 by day 1 in the presence of etoposide and
nutlin-3a. The type 3 proﬁle (Figure 1d) was characterized by
undetectable p53 protein on day 0, and no change in p53 and
p21 expression after in vitro culture in the presence of etoposide
and nutlin-3a.
Cytogenetic data, mutational status and results of the
functional tests are listed in Table 1. We observed that a normal
p53/p21 expression proﬁle (type 1) corresponded to patients
without any TP53 abnormalities (20 patients, no. 1–20) or with a
monoallelic TP53 abnormality (3 patients, no. 21–23), even
though an ATM deletion may be present (cases no. 15–21, 23).
In these patients with a normal response, the only case
displaying a TP53 mutation had a monoallelic mutation on
exon 6 (no. 23). It is important to note that eight patients with
a normal p53/p21 response, who had been tested for p53
phosphorylation, displayed normal results in all cases: this
allowed us to conﬁrm the functionality of the protein.
Nine out of 10 patients with a cytometric type 2 expression
proﬁle had biallelic abnormalities: 8 patients (no. 24–31) had
Table 1 Cytogenetics, mutational status and functional cytometric proﬁles of TP53 in patients with chronic lymphocytic leukemia
Patient no. Functional category (1,2,3) FISH
a TP53 mutation
TP53 del
b ATM del
b Exon/intron
11    UM
21    UM
31    UM
41    UM
51    UM
61    UM
71    UM
81    UM
91    UM
10 1    UM
11 1    UM
12 1    UM
13 1 -   UM
14 1    UM
15 1   + (72%) UM
16 1   + (65%) UM
17 1   + (55%) UM
18 1   + (92%) UM
19 1   + (95%) UM
20 1   + (91%) UM
21 1 + (21%) + (97%) UM
22 1 + (17%)   UM
23 1   + (76%) Exon 6/p.R196P
24 2 + (86%)   Exon 8/p.R273H
25 2 + (80%)   Exon 5/p.H178D
26 2 + (70%)   Exon 5/p.R175H
27 2 + (94%)   Exon 8/p.R273H
28 2 + (79%)   Exon 7/p.R248E
29 2 + (6%)   Exon 7/p.R249S
29 bis 1    UM
30 2 + (53%)   Exon 5/p.P142R and exon 6/m.P222L
31 2 + (91%)   Exon 8/p.V272M
32 2    Intron 9/IVS9+2A4G
33 2   + (84%) UM
34 3 + (87%)   Intron 4/IVS4+1G4A
35 3 + (88%)   Intron 5/IVS5+1G4T
36 3 + (52%)   Intron 6/IVS7 2A4A
37 3 + (17%)   Exon 8/p.Del264L
Abbreviations: FISH, ﬂuorescence in situ hybridization; UM, unmutated.
a200 Interphasic nuclei were counted.
bMonoallelic deletion.
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1 patient had a biallelic mutation on a splice intron site
(intron 9: IVS9þ2A4G; no. 32).
The last patient of this group with type 2 dysfunctional p53
(no. 33) had no TP53 abnormality (no deletions or mutations).
To note that he had an aggressive disease resistant to treatment,
and he died rapidly after a relapse. This pejorative outcome may
be explained by a dysfunctional p53 pathway.
In the subgroup of the four patients with a type 3 p53/p21
expression proﬁle, all had biallelic abnormalities: three patients
had mutations located in a splice intron site (introns 4, 5 and 6;
no. 34–36) and the fourth had a punctual deletion in an exon
(no. 37). The results of these functional tests are summarized in
Table 2.
Our data show that this functional assay is very sensitive.
Indeed, we detected a non-functional p53 in two patients in
whom a small clone was detected by ﬂuorescence in situ
hybridization (no. 29: 6% and no. 37: 17%), and in whom
mutations were not detected by the initial mutational analyses.
For one of these two patients, TP53 status could be studied
longitudinally by comparing the TP53 abnormalities (no. 29)
with a previous sample taken 5 years before (no. 29 bis). Very
interestingly, this previous sample did not have any TP53
abnormalities (no deletions or mutations), and our cytometric
test concluded that it had functional p53 at that time (functional
category 1).
Other aberrations than deletions/mutations of TP53 gene that
can alter function of p53 pathway have been described.
Deletion of chromosome 11 at the locus of the ATM gene
(11q22 deletion) may decrease p53 activity. Although some
authors postulated that in patients with low ATM protein levels,
p53 may not be sufﬁciently activated for induction of apoptosis
in response to DNA damaging agents, we found normal function
of p53 in 6/7 cases where ATM deletion was observed without
any TP53 abnormality. This may be explained by the demon-
stration by Kojima et al.
6 that Nutlin-3a activates p53 and
induces ATM-independent apoptotic activity. The ubiquitine
ligase double-minute protein that controls p53 function may be
overexpressed in cases of single-nucleotide polymorphism
(SNP309), leading to disabled p53 functionality.
7 MicroRNA-
34a has been identiﬁed as a major downstream target of p53,
and it has been demonstrated that low levels of miRNA-34a
are linked to chemotherapy resistance and can impair p53
function.
8
The functional cytometric test described here is a simple and
quick method to detect dysfunction of the p53 protein. The
results of the present study allow us to identify cases where a
functional test could dramatically change the treatment strategy
and the prognosis of the patient. This study allowed us to deﬁne
the feasibility and reliability of this functional assay, and
enabled us to propose its routine usage as a therapeutic strategy
for CLL patients at least to complete if not to replace cytogenetic
and mutational data. In addition, this cytometric functional test
contributes to unraveling the complexity of the p53 pathway.
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Table 2 Results of p53/p21 measured by ﬂow cytometry, according
to the types of expression proﬁles
n Baseline p53 % Increase p53 % Increase p21
Type 1 23 50 (15–90) 314 (118–496) 84 (15–395)
Type 2 10 246 (108–775) 52 (0–134) 3 (0–22)
Type 3 4 62 (37–87) 24 (0–71) 2 (0–6)
Baseline p53: average values and extremes correspond to the mean
ﬂuorescence intensity.
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